Catalog No.
Product Name
Application
Product Information
Citations
-
NF-κB&ERK1/2 Inhibitor
OP-1118 is a potent dual inhibitor of NF-κB and ERK1/2, targeting critical signaling pathways involved in inflammation and cell survival. This compound demonstrates significant anti-inflammatory, cytoprotective, anti-apoptotic, and antibacterial activities by inhibiting the phosphorylation of NF-κB and ERK1/2, leading to a reduction in pro-inflammatory cytokine expression. In preclinical models of Clostridium difficile infection, OP-1118 effectively mitigates toxin-induced intestinal inflammation, cellular damage, and apoptosis, with its protective effects possibly reversible by PMA. This makes OP-1118 a valuable reagent for research into inflammatory conditions and therapeutic interventions. -
Anti-inflammatory Agent
24-O-Acetyllycoclavanol is a triterpenoid compound that functions as an anti-inflammatory agent by selectively targeting the NF-κB and ERK1/2 signaling pathways. Its biological activity includes the inhibition of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), leading to decreased production of inflammatory mediators like nitric oxide (NO), IL-1β, and IL-8. This compound is particularly relevant for research applications in the context of inflammatory bowel disease (IBD) and can be isolated from the ethyl acetate extract of Lycopodium clavatum. -
Anti-inflammatory Agent
Anti-inflammatory agent 31 is a derivative of andrographolide that functions primarily by inhibiting NF-κB activation through the upstream blockade of the PI3K/Akt and ERK1/2 MAPK signaling pathways. This compound exhibits notable anti-inflammatory activity, promoting the recovery of intracellular glutathione (GSH) levels. Additionally, anti-inflammatory agent 31 demonstrates a protective effect on liver cells, making it a valuable tool for research applications in inflammation and hepatoprotection. -
Antioxidant/Anti-inflammatory/Anticancer Agent
Licoflavanone, a flavanone with antioxidant, anti-inflammatory, and anticancer properties, is isolated from the leaf extract of Glycyrrhiza glabra. It exerts its anticancer effects by downregulating the mTOR/PI3K/AKT signaling pathway, leading to inhibition of cancer cell proliferation, migration, and invasion. Additionally, Licoflavanone activates pro-apoptotic factors such as Bax and Bad, along with multiple caspase enzymes. Its anti-inflammatory activity involves reducing NF-κB nuclear translocation and decreasing the phosphorylation of p38, JNK, and ERK1/2, ultimately inhibiting pro-inflammatory cytokines, COX-2, and iNOS expression. This compound is utilized in research on nasopharyngeal carcinoma and its underlying mechanisms. -
CK1α Degrader
INNO-220 is a CRBN-dependent molecular glue degrader that specifically targets CK1α. This orally active compound induces cell cycle arrest at the G0/G1 phase and promotes apoptosis through the degradation of CK1α. Additionally, INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, effectively inhibiting NF-κB signaling in stimulated T cells and lymphoma cells with activating mutations in CARD11. This reagent serves as a valuable tool for advancing research in lymphoma. -
TMA /TMAO Inhinbitor
3,3-Dimethyl-1-butanol is an orally active inhibitor of trimethylamine (TMA) and trimethylamine N-oxide (TMAO), acting via the suppression of the p65 NF-κB signaling pathway and the TGF-β1/Smad3 pathway. This compound exhibits significant potential in the study of cardiovascular diseases (CVD), making it a valuable reagent for researchers investigating the molecular mechanisms underlying these conditions. -
GPR119 Agonist
2-Oleoylglycerol is a GPR119 agonist that activates hGPR119 in transiently transfected COS-7 cells with an EC50 value of 2.5 μM. This lipid enhances the inflammatory response in macrophages and promotes fibrosis through the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. Additionally, 2-Oleoylglycerol stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. Its effects make it a valuable tool for research into non-alcoholic steatohepatitis (NASH) and related metabolic disorders. -
Syk Inhibitor, NF-κB p65 Inhibitor, TGF-β1/Smad Signaling Inhibitor
Flavanomarein is a potent inhibitor of Syk and NF-κB p65, as well as a modulator of TGF-β1/Smad signaling pathways. This compound exhibits cytoprotective, anti-inflammatory, and antioxidant activities, enhancing AKT phosphorylation while regulating key proteins such as PKC-δ, P85α, PKC-β1, Sirt1, Bcl-2, and ICAD. Flavanomarein also inhibits the nuclear translocation of NF-κB p65 and modulates epithelial-mesenchymal transition (EMT) markers, promoting proliferation in HK-2 cells and protecting neuronal cells from 6-OHDA-induced neurotoxicity. This compound is valuable for research on Parkinson's disease and diabetic nephropathy. -
Stable Isotope
2-Oleoylglycerol-d5 is a deuterium-labeled derivative of 2-Oleoylglycerol, a known agonist of GPR119. It exhibits significant biological activity by activating human GPR119 with an EC50 of 2.5 μM in COS-7 cells, enhancing macrophage inflammatory responses and promoting fibrosis through the GPR119/TAK1/NF-κB/TGF-β1 signaling cascade. Additionally, this compound stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol-d5 is particularly useful for studying mechanisms underlying non-alcoholic steatohepatitis (NASH). -
Endogenous Metabolite
9,10-EpOME (9,10-Epoxyoctadecenoic acid) is a cytochrome P450-derived metabolite of linoleic acid. It is known to induce oxidative stress by activating the NF-κB and AP-1 transcription factors and facilitates the chemotaxis of human neutrophils. Additionally, 9,10-EpOME has been shown to induce mechanical and thermal pain in wild-type mice via the PKA pathway. This compound is useful for investigating mechanisms of inflammation and pain in research settings. -
Anti-inflammatory Agent
Anti-inflammatory Agent 58 is a potent inhibitor of IL-1β, demonstrating an IC50 of 1.08 μM. This compound effectively reduces pro-inflammatory gene expression, limits protein secretion, and inhibits NF-κB phosphorylation. It is suitable for research applications focused on inflammatory pathways and the modulation of immune responses. -
Anti-inflammatory Agent
Anti-inflammatory agent 59 is a selective inhibitor of interleukin-1 beta (IL-1β) with an IC50 of 2.28 μM. This compound effectively reduces pro-inflammatory gene expression and protein secretion while inhibiting NF-κB phosphorylation. It serves as a valuable tool in the study of inflammatory pathways and may aid in the development of new therapeutic strategies for inflammatory diseases. -
Anti-inflammatory Agent
Acutissimalignan B is a bioactive compound recognized for its role as an anti-inflammatory agent. It effectively reduces the mRNA expression of key inflammatory cytokines, including inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Additionally, Acutissimalignan B inhibits the phosphorylation of IκBα and the nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) p65, thereby demonstrating potential utility in neuroinflammation research and related disease models. -
NF-κB Inhibitor/TRP Modulator
Cannabitwinol is a selective NF-κB inhibitor and thermosensitive TRP modulator. It effectively inhibits TNFα-induced NF-κB-driven transcription and IL-8 release, exhibiting notable anti-inflammatory and antioxidant properties. Cannabitwinol selectively activates cold-activated TRP channels, such as TRPA1 (EC50 = 3.0 μM), while antagonizing TRPM8 (IC50 = 3.9 μM), with minimal interaction with heat-activated TRP channels like TRPV1 and TRPV2. This compound is applicable in research focused on inflammatory skin diseases, cold allodynia, and hyperalgesia. -
Anti-rotavirus Agent
Norkurarinol is a prenylated flavonoid with significant anti-rotavirus properties. Isolated from Sophora flavescens, it effectively inhibits mushroom tyrosinase DOPA oxidase activity, exhibiting an IC50 of 2.1 μM. Norkurarinol also suppresses poly(I:C)-induced NF-κB and AP-1 activation, while decreasing levels of pro-inflammatory cytokines such as TNF-α and IL-6. Furthermore, it inhibits the phosphorylation of key mitogen-activated protein kinases (p38, JNK, and ERK1/2) and promotes IRF3 phosphorylation, highlighting its potential in antiviral and anti-inflammatory research applications. -
Anti-Inflammatory Agent
Anti-inflammatory agent 102 is a selective inhibitor of the ASK1/p38 MAPKs/NF-κB signaling pathway, exerting notable anti-inflammatory effects. It significantly reduces the release of nitric oxide (NO), reactive oxygen species (ROS), and key inflammatory cytokines, including IL-6, TNF-α, and IL-1β. This compound is valuable for research applications focused on inflammatory diseases, particularly ulcerative colitis (UC). -
Anti-rheumatoid Arthritis Agent
Vitedoamine A is a phenylnaphthalene-type lignan alkaloid with a primary mechanism of IKKβ inhibition, exhibiting an IC50 value of 39 μM. It effectively suppresses the transcriptional activity of NF-κB, leading to decreased production of nitric oxide and reduced expression of inflammatory cytokines such as IL-1β, IL-6, and TNF-α. This compound demonstrates significant potential as an anti-rheumatoid arthritis agent, making it valuable for research focused on inflammatory pathways and therapeutic interventions in rheumatic diseases. -
Anti-inflammatory/hepatoprotective Agent
Isostrictiniin is a polyphenolic compound derived from Nymphaea candida, functioning as an anti-inflammatory and hepatoprotective agent. It enhances the expression of Nrf2 and HO-1 while inhibiting Keap1, leading to the reduction of phosphorylation levels of key proteins such as JNK, ERK1/2, p38, IκBα, and NF-κB p65. Isostrictiniin effectively decreases pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, and PGE2, demonstrating protective effects against acute lung injury induced by LPS and acute alcoholic liver injury. Its multifaceted activities encompass anti-inflammatory, antioxidant, and anti-fibrotic properties, making it a valuable tool in biochemical research. -
STING Activator
c-(2'FdAMP-2'FdIMP) is a cyclic dinucleotide (CDN) that functions as a STING activator. It effectively stimulates STING-dependent signaling pathways, including IRF and NF-κB, leading to enhanced immune responses. This compound is valuable for research into STING-based immunotherapy applications, particularly in the context of cancer and infectious disease studies. -
NF-κB Inhibitor
Bengamide B is a potent inhibitor of NF-κB with an IC50 of 85 nM. This compound effectively reduces LPS-induced expression of pro-inflammatory cytokines, including TNF-α, IL-6, and MCP-1, demonstrating significant anti-inflammatory activity. Additionally, Bengamide B displays antitumor efficacy, with an IC50 of 2 nM against HCT-116 colorectal cancer cells, making it a valuable reagent for research in inflammation and oncology. -
Flavone Glycosides
Quercetagitrin, a flavone glycoside, is derived from the African marigold (Tagetes erecta) and exhibits notable anti-inflammatory properties. It effectively inhibits Tau accumulation, reversing neuroinflammation and cognitive deficits in P301S-Tau transgenic mouse models by suppressing NF-κB activation. Additionally, Quercetagitrin acts as a dual-target inhibitor of PTPN6 (IC50 = 1 μM) and PTPN9 (IC50 = 1.7 μM). This compound enhances glucose uptake in mature C2C12 myoblasts, making it relevant for studies related to Alzheimer’s disease and type 2 diabetes. -
SEAP Inhibitor
Cycloepoxydon is a potent inhibitor of secreted alkaline phosphatase (SEAP) expression, targeting both NF-κB and AP-1 signaling pathways. It effectively reduces PMA-induced SEAP expression with IC50 values ranging from 1-2 μg/mL (4.2-8.4 μM) for NF-κB and 3-5 μg/mL (12.6-21 μM) for AP-1. This compound is valuable for research applications involving inflammation, cancer biology, and signal transduction studies. -
STAT3 Agonist
ML115 is a selective agonist of the signal transducer and activator of transcription 3 (STAT3) with an EC50 of 2 nM. It enhances the expression of BCL3, a STAT3-dependent oncogene, while demonstrating inactivity towards related targets such as STAT1, STAT5, and NF-κB. ML115 has been shown to counterbalance the effects of Ginsenoside Rc on cell viability and inflammatory responses in LPS-stimulated H9c2 and RAW264.7 cells, impacting oxidative stress markers. This compound is valuable for investigating mechanisms in breast and prostate cancer research. -
NF-κB Inhibitor
2,4,5-Trimethoxybenzoic acid is an NF-κB inhibitor with notable anti-inflammatory properties. This compound, derived from purple perilla extracts, effectively inhibits LPS-induced inflammatory responses by blocking the activation of NF-κB and STAT signaling pathways. It has been shown to suppress M1 macrophage phenotype-mediated inflammation, making it a valuable tool for research into diabetes and related inflammatory conditions. -
Anti-inflammation Agent
Thienodolin is an alkaloid with potent anti-inflammatory properties, targeting the inhibition of nitric oxide production in LPS-stimulated RAW 264.7 murine macrophage cells, exhibiting an IC50 value of 17.2 μM. It effectively suppresses inducible nitric oxide synthase (iNOS), prevents IκBα degradation, and reduces NF-κB p65 nuclear translocation while modulating the phosphorylation of STAT1 at Tyr701. Thienodolin serves as a valuable tool for research into inflammatory processes and pathways. -
Anti-inflammatory/antibacterial Agent
Plumericin is an anti-inflammatory and antibacterial agent that primarily targets key signaling pathways involved in inflammation and cellular stress response. It has been shown to reduce apoptosis, activate Nrf-2, and inhibit both NF-κB and AhR activation, while also blocking STAT3 signaling. Plumericin exhibits inhibitory effects on Mycobacterium tuberculosis growth, making it a valuable compound for studying chronic kidney disease, vascular diseases, inflammatory bowel diseases, peritonitis, and tuberculosis. -
CRFR Agonist
Urocortin II, human is a selective agonist of the type-2 corticotropin-releasing factor (CRF2) receptor, exhibiting key biological activities that include promoting satiety and providing neuroprotective effects. This peptide also demonstrates bactericidal and antiparasitic properties, as well as pro-inflammatory activity. Additionally, Urocortin II, human can activate the NF-κB pathway and ERK1/2 MAP kinase, making it relevant for research in pulmonary arterial hypertension and cardiac protection. Its diverse applications extend to studies in infection, inflammation, metabolic disorders, neurological conditions, and cardiovascular diseases. -
Flavones
Flavanone is a naturally occurring flavone that functions as an inhibitor of human estrogen synthetase (aromatase). It targets the ERK/p38/NF-κB signaling pathway, demonstrating potential in mitigating oncogenic processes. Flavanone has shown oral bioactivity and possesses antitumor efficacy, making it a valuable reagent for research in cancer biology and hormone-related studies. -
Anti-inflammatory Agent
Fluorofenidone is an orally active anti-inflammatory agent that exhibits anti-fibrotic and antioxidant properties. It functions by downregulating ACSL4 expression, upregulating GPX4, and inhibiting the NF-κB signaling pathway, thereby alleviating inflammation and fibrosis. In preclinical models, Fluorofenidone has demonstrated efficacy in ameliorating cholestasis and fibrosis by modulating the hepatic Erk/Egr-1 signaling and TGFβ1/Smad pathways. This compound is particularly relevant for research into chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF), and non-small cell lung cancer (NSCLC). -
IKKε/TBK-1 Inhibitor
MRT67307 hydrochloride is a selective inhibitor of IKKε and TBK-1, exhibiting IC50 values of 160 nM and 19 nM, respectively. Additionally, it inhibits ULK1 and ULK2 with IC50s of 45 nM and 38 nM, respectively. This compound is employed in research to study autophagy regulation and related cellular processes. It is particularly useful in investigations of inflammatory signaling pathways and cancer biology. -
Essential Amino Acid
L-Cysteine hydrochloride hydrate is an essential amino acid that serves as a precursor for biologically active molecules, including hydrogen sulfide (H2S), glutathione, and taurine. It modulates the CBS/H2S pathway and has been shown to inhibit NF-κB activation, as well as regulate insulin and ghrelin secretion. This compound is involved in reducing blood glucose levels, vascular inflammation markers, and appetite, while also being noted for its potential to induce kidney damage. Its applications extend to research on neurological diseases and diabetes. -
HDAC Inhibitor
HDAC-IN-37 is a potent inhibitor of histone deacetylases (HDACs), demonstrating IC50 values of 0.0551 μM for HDAC1, 1.24 μM for HDAC3, 0.948 μM for HDAC8, and 34.2 μM for HDAC6. This compound effectively increases histone acetylation through a slow-off binding mechanism. Additionally, HDAC-IN-37 disrupts the transition from the G1 phase to the S phase of the cell cycle and promotes early apoptosis in various cell types, making it a valuable tool for research in cancer biology and therapeutic development. -
NF-κB Activator
Isochamaejasmin is a biflavonoid that acts as a potent activator of NF-κB. It exhibits significant anti-cancer properties by inducing apoptosis through the mitochondrial pathway and causing DNA damage in AW1 cells. In addition, Isochamaejasmin demonstrates moderate antiplasmodial activity against P. falciparum with an IC50 of 7.3 μM, while maintaining relatively low cytotoxicity (CC50 of 29.0 μM), making it valuable for various biological research applications. -
c-Met/HDAC Inhibitor
c-Met/HDAC-IN-3 is a dual inhibitor targeting c-Met and histone deacetylase 1 (HDAC1), exhibiting IC50 values of 12.50 nM and 26.97 nM, respectively. This compound demonstrates significant biological activity by inducing apoptosis and causing cell cycle arrest at the G2/M phase. c-Met/HDAC-IN-3 serves as a valuable tool for research in cancer biology and therapeutic development, particularly in studies focused on synergistic inhibition of oncogenic pathways. -
HDAC6 Inhibitor
HDAC6-IN-4 is a potent and selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 value of 23 nM. This compound promotes apoptosis in cancer cells and demonstrates significant antitumor efficacy while exhibiting minimal toxicity. HDAC6-IN-4 is valuable for research in cancer biology, particularly in studies focused on epigenetic regulation and therapeutic development. -
HDAC Inhibitor
HDAC-IN-31 is a selective and orally active histone deacetylase (HDAC) inhibitor, exhibiting IC50 values of 84.90 nM for HDAC1, 168.0 nM for HDAC2, 442.7 nM for HDAC3, and greater than 10,000 nM for HDAC8. This compound induces apoptosis and triggers G2/M phase cell cycle arrest, demonstrating significant antitumor efficacy. HDAC-IN-31 is applicable in research focused on diffuse large B-cell lymphoma and other cancer studies. -
Topoisomerase/HDAC Inhibitor
Top/HDAC-IN-1 is a dual inhibitor targeting both topoisomerase and histone deacetylases (HDACs), demonstrating IC50 values of 18 nM for HDAC1, 230 nM for HDAC2, 790 nM for HDAC3, 87 nM for HDAC6, and 5250 nM for HDAC8. This compound exhibits significant antitumor activity against HCT116 cells, with an IC50 of 180 nM, effectively inducing apoptosis and promoting G2 cell cycle arrest. Top/HDAC-IN-1 serves as a valuable tool in cancer research, particularly for studies involving epigenetic modulation and cell proliferation. -
mTOR/HDAC6 Inhibitor
mTOR/HDAC6-IN-1 is a potent dual inhibitor targeting mTOR and HDAC6, exhibiting IC50 values of 133.7 nM and 56 nM, respectively. This compound is known to induce significant autophagy and apoptosis while suppressing cell migration. It holds potential for research applications in triple-negative breast cancer (TNBC) studies, offering insights into the interplay between these critical pathways in cancer progression. -
HDAC Inhibitor
HDAC-IN-59 is a potent inhibitor of histone deacetylases (HDACs), demonstrating significant biological activity in cancer research. This compound promotes the generation of reactive oxygen species (ROS), leading to DNA damage and the induction of apoptosis via the mitochondria-related pathway. Additionally, HDAC-IN-59 effectively disrupts the cell cycle at the G2/M phase, making it a valuable tool for studying the mechanisms of cell growth regulation and apoptosis in various cancer models. -
Antitumor Agent
SpiD3, a spirocyclic dimer, functions as an antitumor agent with significant inhibitory effects on malignant B-cell proliferation. It suppresses NF-κB activation independently of tumor microenvironment-related stimuli, promoting apoptosis and inhibiting protein synthesis in chronic lymphocytic leukemia (CLL) cells. SpiD3 is suitable for research focused on the mechanisms of CLL and the development of targeted therapies. -
S100P Inhibitor
5-Methyl cromolyn disodium is a selective inhibitor of the S100P protein, targeting its interaction with the receptor for advanced glycation end-products (RAGE). It effectively suppresses NF-κB activity and cell proliferation while enhancing Gemcitabine-induced apoptosis. In preclinical mouse models, 5-Methyl cromolyn disodium demonstrates significant anti-tumor effects by reducing growth and metastasis of pancreatic ductal adenocarcinoma (PDAC), ultimately extending survival. This compound serves as a valuable tool for investigating pancreatic cancer mechanisms and potential therapeutic approaches. -
JAK/HDAC Inhibitor
JAK/HDAC-IN-2 is a dual-target inhibitor of Janus kinase (JAK) and histone deacetylase (HDAC), specifically inhibiting HDAC3/6 and JAK1/2 with nanomolar potency. This compound demonstrates proapoptotic activity by inhibiting histone deacetylation and STAT3 phosphorylation, contributing to its mechanism of action. JAK/HDAC-IN-2 exhibits significant antiproliferative effects in various hematological malignancies and solid tumors, making it a valuable tool for cancer research and therapeutic studies. -
c-Met/HDAC Inhibitor
c-Met/HDAC-IN-2 is a highly potent dual inhibitor targeting c-Met and histone deacetylases (HDACs), exhibiting IC50 values of 18.49 nM for HDAC1 and 5.40 nM for c-Met. This compound demonstrates significant antiproliferative effects against various cancer cell lines, notably inducing G2/M-phase cell cycle arrest and apoptosis in HCT-116 cells. c-Met/HDAC-IN-2 is a valuable tool for investigating mechanisms of anti-cancer resistance and exploring therapeutic strategies in oncology research. -
HDAC inhibitor
HDAC-IN-67 is a potent inhibitor of histone deacetylases HDAC1 and HDAC6, demonstrating IC50 values of 22 nM and 8 nM, respectively. This compound effectively inhibits cell proliferation and induces apoptosis in various cancer cell lines. Its significant antitumor activity makes HDAC-IN-67 a valuable tool for cancer research and a potential candidate for therapeutic development. -
PIM-1/HDAC Inhibitor
PIM-1/HDAC-IN-1 is a selective inhibitor of PIM-1 as well as histone deacetylases HDAC 1 and HDAC 6, exhibiting an IC50 of 343.87 nM for PIM-1 and 63.65 nM and 62.39 nM for HDAC 1 and HDAC 6, respectively. This compound demonstrates significant apoptotic activity in MCF-7 cell lines, inducing pre-G1 apoptosis and causing cell cycle arrest at the G2/M phase. PIM-1/HDAC-IN-1 is a valuable tool for research on cancer biology and the regulation of cell proliferation and apoptosis. -
FGFR/HDAC Inhibitor
HDAC-IN-50 is a potent dual inhibitor targeting FGFR and HDAC with IC50 values of 0.18 nM for FGFR1, 1.2 nM for FGFR2, 0.46 nM for FGFR3, 1.4 nM for FGFR4, and varying inhibitory effects on HDAC isoforms such as HDAC1 (1.3 nM), HDAC2 (1.6 nM), HDAC6 (2.6 nM), and HDAC8 (13 nM). This compound effectively induces apoptosis and causes cell cycle arrest at the G0/G1 phase. Additionally, HDAC-IN-50 decreases the expression of phosphorylated forms of FGFR1, ERK, and STAT3, indicating its potential applications in cancer research and therapy. -
Tubulin/HDAC Inhibitor
Tubulin/HDAC-IN-1 is a dual inhibitor targeting tubulin and histone deacetylase 8 (HDAC8) through CH/π interaction and hydrogen bonding, respectively. This compound effectively inhibits tubulin polymerization and selectively inhibits HDAC8 with an IC50 value of 150 nM. Tubulin/HDAC-IN-1 demonstrates cytotoxic effects against a range of human cancer cell lines, induces cell cycle arrest in the G2/M phase, and promotes apoptosis. It is a valuable reagent for research involving hematologic malignancies and solid tumors, including neuroblastoma and leukemia. -
HDAC6 Inhibitor
SAHA-OH is a selective inhibitor of histone deacetylase 6 (HDAC6) with an IC50 of 23 nM, demonstrating a 10- to 47-fold selectivity over HDAC isoforms 1, 2, 3, and 8. This compound exhibits notable anti-inflammatory properties and has been shown to reduce macrophage apoptosis. It is a valuable tool for research focused on the modulation of histone acetylation and the investigation of HDAC6's role in various inflammatory pathways. -
VEGFR-2/HDAC Dual Inhibitor
VEGFR2/HDAC1-IN-1 is a potent dual inhibitor of VEGFR-2 and HDAC, demonstrating IC50 values of 57.83 nM and 9.82 nM, respectively. This compound effectively arrests the cell cycle at the S and G2 phases, leading to apoptosis in HeLa cells. Additionally, VEGFR2/HDAC1-IN-1 exhibits significant anti-angiogenic properties, making it a valuable tool for research in cancer biology and targeted therapies. -
HDAC Inhibitor
HDAC-IN-34 is a potent inhibitor of histone deacetylases (HDACs), demonstrating IC50 values of 0.022 μM for HDAC1 and 0.45 μM for HDAC6. This compound binds to DNA, leading to DNA damage and inducing apoptosis through the p53 signaling pathway. Additionally, HDAC-IN-34 exhibits significant anti-proliferative effects against HCT-116 colorectal cancer cells, with an IC50 of 1.41 μM, making it a valuable tool for cancer research and epigenetic studies.
